Company
General Electric
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
1
510(k), De Novo and PMA
Device trials
2
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
58
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
GE
NYSE · GENERAL ELECTRIC CO
Public float
$270.2B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$45.9B
Fiscal year ending Dec 31, 2025
Net income
$8.70B
Fiscal year ending Dec 31, 2025
R&D spending
$1.58B
Fiscal year ending Dec 31, 2025
Cash
$8.76B
As of Sep 30, 2026
Long-term debt
$17.0B
As of Sep 30, 2026
Shares outstanding
1033.4M
As of Sep 30, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $1.99B | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- Et ControlPMA
P210018 · Decided Mar 17, 2022 · 318 days after receipt
Device type: Software option for anesthesia gas machine to achieve and maintain targeted end tidal oxygen and anesthetic agents (QSF) · Anesthesiology & Respiratory
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT05796492 · 8 participants · Start Jun 22, 2023 · Primary completion Dec 18, 2024
Device: Pulsed splenic ultrasound; Ultrasound probe (no energy applied) · For: Burn Wound; 2nd Degree Burn of the Skin
Sites: Los Angeles, California
- Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DMCompleted
NCT04502212 · 16 participants · Start Jul 30, 2020 · Primary completion May 24, 2021
Device: Hepatic Ultrasound Insonification · For: Type 2 Diabetes
Sites: Chula Vista, California
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 1 | 0 | 0 |
| Oct 24 | 0 | 1 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- GE ApexPro Oximeter systems (ApexPro CH or ApexPro FH with ApexPro Telemetry version 3.9 software)Terminated
Z-0631-2010 · Started Sep 25, 2009 · Posted by FDA Jan 13, 2010
Reason given: Potential misuse of the ApexPro Telemetry System and incorrect message and alarm information in the ApexPro Operator's Manual may impact patient safety. When ApexPro Telemetry systems are used with SpO2 oximeters: 1. ApexPro FH Transceiver can operate with the ApexPro FH Xpod connected, but without ECG lead wires...
Cause as FDA categorized it: Labeling design · Device type: Oximeter (DQA)
Z-0519-2008 · Started Nov 8, 2007 · Posted by FDA Jan 17, 2008
Reason given: Potential for Loss of Audible Alarming and ECG Tab Setting Changes; from Clinical Informaiton Center (CIC) Pro v5.0.3 & 5.0.6 when used in combination with Telemetry and bedside monitors.
Cause as FDA categorized it: Software design · Device type: Detector And Alarm, Arrhythmia (DSI)
- GE Healthcare Innova 4100/4100 IQ. Digital Fluoroscopic Imaging System (Vascular Angiography System)Terminated
Z-0869-2007 · Started Mar 26, 2007 · Posted by FDA Jun 5, 2007
Reason given: Measurement errors during the computation of vessel diameters while using the Stenosis Analysis software (also known as Quantitative Coronary Analysis function-QCA) using the auto-calibration function on Innova Digital (located in control room) or in-room InnovaCentral/Touch-Screen
Cause as FDA categorized it: Other · Device type: Solid State X-Ray Imager (Flat Panel/Digital Imager) (MQB)
55 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.